Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

STTK

Shattuck Labs Inc

Feb 13 • 04:00PM ET

3.86

-0.05 -1.28 %

Healthcare • Biotechnology • USA • NASD

Peers: KURA ADAP FATE DTIL AFMD ALXO HOOK ALDX IMTX

| Held by: VTI VXF AVSC QQQS DFAS TMED

Index	-	P/E	-	EPS (ttm)	-1.02	Insider Own	21.56%	Shs Outstand	63.15M	Perf Week	2.39%
Market Cap	244.26M	Forward P/E	-	EPS next Y	-0.52	Insider Trans	-	Shs Float	49.64M	Perf Month	-18.39%
Enterprise Value	160.76M	PEG	-	EPS next Q	-0.14	Inst Own	60.17%	Short Float	4.54%	Perf Quarter	101.04%
Income	-54.90M	P/S	244.26	EPS this Y	48.51%	Inst Trans	5.10%	Short Ratio	4.19	Perf Half Y	348.63%
Sales	1.00M	P/B	2.61	EPS next Y	32.39%	ROA	-51.77%	Short Interest	2.25M	Perf YTD	5.75%
Book/sh	1.48	P/C	2.84	EPS next 5Y	32.60%	ROE	-57.84%	52W High	4.89 -21.06%	Perf Year	208.80%
Cash/sh	1.36	P/FCF	-	EPS past 3/5Y	-11.56% -20.93%	ROIC	-57.79%	52W Low	0.69 457.68%	Perf 3Y	-14.98%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-42.45% -10.36%	Gross Margin	-272.20%	Volatility	8.20% 8.55%	Perf 5Y	-91.38%
Dividend TTM	-	EV/Sales	160.76	EPS Y/Y TTM	33.32%	Oper. Margin	-5770.30%	ATR (14)	0.32	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	17.00	Sales Y/Y TTM	-84.46%	Profit Margin	-5489.50%	RSI (14)	47.96	Recom	1.67
Dividend Gr. 3/5Y	- -	Current Ratio	17.00	EPS Q/Q	57.53%	SMA20	-4.63%	Beta	1.56	Target Price	7.25
Payout	-	Debt/Eq	0.03	Sales Q/Q	-66.63%	SMA50	2.61%	Rel Volume	0.27	Prev Close	3.91
Employees	44	LT Debt/Eq	0.02	Earnings	Nov 06 AMC	SMA200	93.61%	Avg Volume	537.43K	Price	3.86
IPO	Oct 09, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	5.79% -	Trades		Volume	146,302	Change	-1.28%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-26	Initiated	Piper Sandler	Overweight	$15
Dec-01-25	Upgrade	H.C. Wainwright	Neutral → Buy	$6
Sep-08-25	Initiated	Wedbush	Outperform	$4
Mar-17-25	Initiated	Leerink Partners	Outperform	$4
Oct-02-24	Downgrade	Needham	Buy → Hold
Oct-02-24	Downgrade	Citigroup	Buy → Neutral	$8 → $2
Oct-01-24	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-17-24	Downgrade	BTIG Research	Buy → Neutral
Aug-31-22	Initiated	BTIG Research	Buy	$12
Jun-01-22	Initiated	Citigroup	Buy	$13
May-02-22	Initiated	H.C. Wainwright	Buy	$28
Apr-14-21	Initiated	Berenberg	Buy	$47
Jan-11-21	Initiated	Evercore ISI	Outperform
Nov-03-20	Initiated	Needham	Buy	$34
Nov-03-20	Initiated	Cowen	Outperform
Nov-03-20	Initiated	Citigroup	Buy	$36

Show Previous Ratings

Feb-06-26 08:30AM	Shattuck Labs Announces Participation in Upcoming Piper Sandler Virtual Novel Targets in Immunology Symposium (GlobeNewswire) +5.60%
Jan-05-26 10:50PM	Why Shattuck Labs Stock Soared in December (Motley Fool)
Dec-15-25 04:15PM	Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-29-25 01:26AM	Analyst Confidence Upbeat on Shattuck Labs (STTK) Amid SL-325 Progress and Earlier Q3 2025 Result (Insider Monkey)
Nov-20-25 08:00AM	Shattuck Labs to Participate in Upcoming December Investor Conferences (GlobeNewswire)
04:30PM	Loading…
Nov-06-25 04:30PM	Shattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Oct-08-25 12:00PM	What Makes Shattuck Labs, Inc. (STTK) a Strong Momentum Stock: Buy Now? (Zacks)
Oct-02-25 07:51AM	Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel (GlobeNewswire)
Sep-19-25 09:55AM	Should You Buy Shattuck Labs, Inc. (STTK) After Golden Cross? (Zacks)
Sep-08-25 05:09PM	Shattuck Labs (STTK) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) +21.29% +6.91%
Aug-26-25 06:30AM	Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors (GlobeNewswire)
Aug-21-25 10:17AM	Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease (GlobeNewswire) -11.42%
Aug-14-25 06:30AM	Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) +6.13%
Aug-05-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +33.30%
06:30AM	Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million (GlobeNewswire)
07:00AM	Loading…
Jul-02-25 07:00AM	Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism (GlobeNewswire)
May-01-25 04:20PM	Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) +9.20% -7.81%
Apr-02-25 05:00PM	Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire) +16.28% -17.34%
Mar-27-25 07:00AM	Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-20-25 09:00AM	Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025 (GlobeNewswire)
Feb-13-25 04:30PM	Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025 (GlobeNewswire) +5.04% +6.40%
Feb-04-25 07:00AM	Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn's and Colitis Congress (GlobeNewswire)
Jan-06-25 04:59PM	Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.22%
Jan-03-25 07:15AM	Shattuck Labs highlights upcoming key milestones in 2025 (TipRanks) +10.74%
Jan-02-25 07:00AM	Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025 (GlobeNewswire)
Nov-25-24 07:00AM	Shattuck Labs Announces Participation in Upcoming December Conferences (GlobeNewswire)
Nov-15-24 07:12AM	Shattuck Labs sees cash runway into 2027 (TipRanks) -9.85%
Nov-14-24 07:00AM	Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire) +12.30%
Oct-24-24 09:35AM	Down -64.19% in 4 Weeks, Here's Why Shattuck Labs (STTK) Looks Ripe for a Turnaround (Zacks)
Oct-08-24 09:35AM	After Plunging -68.96% in 4 Weeks, Here's Why the Trend Might Reverse for Shattuck Labs (STTK) (Zacks) +11.50%
11:32AM	Loading…
Oct-02-24 11:32AM	Shattuck Labs stock craters following pipeline and job cuts (Pharmaceutical Technology) -34.90%
06:57AM	Shattuck Labs Refocuses Strategy Amidst Restructuring and Cuts (TipRanks)
Oct-01-24 12:26PM	Shattuck Labs Shutters Cancer Program, Lays Off Around 40% Of Its Workforce, Reorganizes Pipeline (Benzinga) -44.99%
06:30AM	Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway (GlobeNewswire)
Aug-01-24 06:20PM	Shattuck Labs, Inc. (STTK) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -5.28%
04:05PM	Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Jul-30-24 05:00PM	Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jul-01-24 06:00AM	Shattuck Labs Announces Addition to Russell 2000 and Russell 3000 Indexes (GlobeNewswire)
Jun-18-24 06:25PM	Yigal Nochomovitz Just Trimmed Price Target for Shattuck Labs, Inc. (NASDAQ:STTK) (Insider Monkey) -7.83% -9.26%
10:48AM	Wall Street Analysts Just Trimmed Price Targets for These 10 Stocks (Insider Monkey)
Jun-14-24 01:28PM	Shattuck (STTK) Announces Positive Interim Data on Cancer Drug (Zacks) -9.50%
06:00AM	Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients (GlobeNewswire)
Jun-10-24 07:30AM	Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML) (GlobeNewswire)
Jun-06-24 07:30AM	Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients (GlobeNewswire)
May-21-24 09:35AM	After Plunging -19.89% in 4 Weeks, Here's Why the Trend Might Reverse for Shattuck Labs (STTK) (Zacks)
May-14-24 04:15PM	Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the European Hematology Association (EHA) 2024 Congress (GlobeNewswire) -18.07%
May-07-24 12:00PM	What Makes Shattuck Labs (STTK) a New Buy Stock (Zacks)
09:55AM	Does Shattuck Labs (STTK) Have the Potential to Rally 34.17% as Wall Street Analysts Expect? (Zacks)
May-04-24 05:31AM	Shattuck Labs Inc (STTK) Reports First Quarter 2024 Financial Results (GuruFocus.com)
May-02-24 09:58PM	STTK Stock Earnings: Shattuck Labs Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:25AM	Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:05AM	Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-09-24 04:05PM	Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024 (GlobeNewswire) +8.44%
Apr-01-24 07:00AM	Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-04-24 07:00AM	Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors (GlobeNewswire)
Feb-29-24 04:05PM	Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights (GlobeNewswire) +10.54%
Feb-26-24 07:00AM	Shattuck Labs Announces Participation in Upcoming March Conferences (GlobeNewswire)
Feb-14-24 05:06AM	Ono Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion Proteins (PR Newswire) +6.03%
Feb-13-24 06:00AM	Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases (GlobeNewswire) -5.37%
Jan-08-24 07:00AM	Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024 (GlobeNewswire) +14.94%
Jan-04-24 04:05PM	Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +12.14%
Dec-21-23 08:00AM	Shattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants (GlobeNewswire)
Dec-13-23 10:45AM	Why Is Shattuck Labs (STTK) Stock Up 93% Today? (InvestorPlace) +130.33%
06:00AM	Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients (GlobeNewswire)
Dec-05-23 04:15PM	Shattuck Labs to Host Investor Call and Webcast to Share Initial Clinical Trial Data from Phase 1A/B Dose-Expansion Cohorts in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53m Acute Myeloid Leukemia (AML) and Review of Dose-Escalation Data from the American Society of Hematology (ASH) 2023 Annual Meeting on December 13, 2023 (GlobeNewswire) +22.56%
Nov-14-23 09:00AM	Shattuck Labs Announces Participation in Upcoming 6th Annual Evercore ISI HealthCONx Conference (GlobeNewswire) +10.05%
Nov-13-23 08:52AM	Shattuck Labs, Inc. (NASDAQ:STTK) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 11:54PM	Q3 2023 Shattuck Labs Inc Earnings Call (Thomson Reuters StreetEvents) -23.21%
08:29AM	Shattuck Labs Inc (STTK) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com)
06:00AM	Shattuck Labs Reports Third Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-06-23 09:28AM	Shattuck Labs to Report Third-Quarter 2023 Financial Results on November 9, 2023 (GlobeNewswire) +14.05%
Nov-02-23 09:01AM	Shattuck Labs to Present Topline Data from Phase 1 A/B Clinical Trial of SL-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS) Patients at the American Society of Hematology (ASH) 2023 Annual Meeting (GlobeNewswire)
Oct-24-23 12:30PM	10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis (ACCESSWIRE) +7.69%
Aug-10-23 05:15PM	Shattuck Labs, Inc. (STTK) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -8.64%
04:00PM	Shattuck Labs Reports Second Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Jul-06-23 10:14AM	Companies Like Shattuck Labs (NASDAQ:STTK) Could Be Quite Risky (Simply Wall St.) -7.07%
May-25-23 05:15PM	Shattuck Labs to Present Complete Dose-Escalation Data from Phase 1A Monotherapy Clinical Trial of SL-172154 in Platinum-Resistant Ovarian Cancer (PROC) at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting (GlobeNewswire) -5.46%
May-09-23 05:15PM	Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +5.56%
04:00PM	Shattuck Labs Reports First Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-03-23 07:00AM	Shattuck Labs Announces Participation in Upcoming 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-21-23 11:50AM	Great week for Shattuck Labs, Inc. (NASDAQ:STTK) institutional investors after losing 37% over the previous year (Simply Wall St.)
Mar-16-23 08:31AM	Shattuck Labs Presents Preclinical Data at the 2023 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) +8.93%
Mar-01-23 07:00AM	Shattuck Labs Announces Participation in Upcoming March Conferences (GlobeNewswire)
Feb-27-23 10:46PM	Shattuck Labs, Inc. (NASDAQ:STTK) Q4 2022 Earnings Call Transcript (Insider Monkey)
Feb-23-23 04:30PM	Shattuck Labs Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-16-23 07:00AM	Shattuck Labs to Report Fourth-Quarter and Full-Year 2022 Financial Results on February 23, 2023 (GlobeNewswire)
Feb-09-23 06:01AM	Shattuck Labs Announces Participation in Upcoming SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-27-23 08:34AM	We Think Shattuck Labs (NASDAQ:STTK) Needs To Drive Business Growth Carefully (Simply Wall St.)
Jan-09-23 07:00AM	Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2023 (GlobeNewswire)
Dec-13-22 06:51AM	Multiple insiders bought Shattuck Labs, Inc. (NASDAQ:STTK) stock earlier this year, a positive sign for shareholders (Simply Wall St.)
Dec-01-22 09:55AM	Shattuck Labs, Inc. (STTK) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Nov-11-22 05:51AM	Shattuck Labs Third Quarter 2022 Earnings: US$0.58 loss per share (vs US$0.41 loss in 3Q 2021) (Simply Wall St.)
Nov-08-22 04:30PM	Shattuck Labs Reports Third Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire) -6.75% -5.88%
Nov-07-22 08:00AM	Shattuck Labs Presents Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Nov-04-22 11:55AM	Investors in Shattuck Labs (NASDAQ:STTK) have unfortunately lost 86% over the last year (Simply Wall St.)
Nov-03-22 08:30AM	Shattuck Labs Announces Participation in Upcoming November Conferences (GlobeNewswire)
Nov-01-22 04:30PM	Shattuck Labs to Report Third Quarter 2022 Financial Results on November 8, 2022 (GlobeNewswire) -8.66%
Oct-12-22 10:04AM	Owning 38% shares,institutional owners seem interested in Shattuck Labs, Inc. (NASDAQ:STTK), (Simply Wall St.) +10.51%
Oct-05-22 04:30PM	Shattuck Labs to Present Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 8-12 (GlobeNewswire) +10.00%
Sep-01-22 04:15PM	Shattuck Labs Announces Participation in Upcoming September Conferences (GlobeNewswire)

Shattuck Labs, Inc. is a biotechnology company, which engages in the research and development of potential treatments for inflammatory and immune-mediated diseases. It focuses on developing a potential first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company was founded by Josiah C. Hornblower and Taylor Schreiber in 2016 and is headquartered in Austin, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ORBIMED ADVISORS LLC	Director	Aug 25 '25	Buy	0.87	6,306,127	5,471,826	5,255,106	Sep 02 09:52 PM
Ashiya Mona	Director	Aug 25 '25	Buy	0.87	6,306,127	5,471,826	5,255,106	Sep 02 09:50 PM

Open in Screener

IRON

Disc Medicine Inc

Feb 13 • 04:00PM ET

55.95

-15.70 -21.91 %

Healthcare • Biotechnology • USA • NASD

IRON Disc Medicine Inc daily Stock Chart

Peers: VRTX ALNY CRSP BEAM EDIT NTLA SRPT IONS BLUE SGMO

| Held by: VTI XBI IWM VXF IWO IBB SCHA VTWO VHT ITOT

Index	RUT	P/E	-	EPS (ttm)	-5.36	Insider Own	27.99%	Shs Outstand	35.01M	Perf Week	-29.82%
Market Cap	2.11B	Forward P/E	-	EPS next Y	-6.85	Insider Trans	-10.48%	Shs Float	27.18M	Perf Month	-27.41%
Enterprise Value	1.53B	PEG	-	EPS next Q	-1.75	Inst Own	83.32%	Short Float	15.09%	Perf Quarter	-34.96%
Income	-181.11M	P/S	-	EPS this Y	-55.39%	Inst Trans	3.85%	Short Ratio	7.13	Perf Half Y	-7.86%
Sales	0.00M	P/B	3.42	EPS next Y	-11.32%	ROA	-32.18%	Short Interest	4.10M	Perf YTD	-29.54%
Book/sh	16.38	P/C	3.43	EPS next 5Y	-12.37%	ROE	-34.78%	52W High	99.50 -43.77%	Perf Year	3.42%
Cash/sh	16.32	P/FCF	-	EPS past 3/5Y	54.09% 38.12%	ROIC	-30.00%	52W Low	30.82 81.54%	Perf 3Y	131.39%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	22.11% 9.45%	Perf 5Y	-55.45%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-34.96%	Oper. Margin	-	ATR (14)	6.27	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	23.45	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	25.21	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	23.45	EPS Q/Q	-99.39%	SMA20	-26.28%	Beta	0.86	Target Price	115.08
Payout	-	Debt/Eq	0.05	Sales Q/Q	-	SMA50	-30.61%	Rel Volume	8.68	Prev Close	71.65
Employees	84	LT Debt/Eq	0.05	Earnings	Nov 06 BMO	SMA200	-17.55%	Avg Volume	574.94K	Price	55.95
IPO	Aug 12, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-22.74% -	Trades		Volume	4,989,722	Change	-21.91%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-03-25	Resumed	Stifel	Buy	$125
Jul-21-25	Initiated	Truist	Buy	$86
Jul-03-25	Resumed	Morgan Stanley	Overweight	$85
Jun-11-25	Resumed	Raymond James	Strong Buy	$89
Feb-27-25	Initiated	TD Cowen	Buy
Nov-05-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$85
Nov-04-24	Upgrade	Raymond James	Outperform → Strong Buy	$66 → $110
Oct-23-24	Initiated	Jefferies	Buy	$89
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Aug-22-24	Initiated	Wells Fargo	Overweight	$75
Apr-01-24	Downgrade	Raymond James	Strong Buy → Outperform	$40
Dec-19-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$56 → $65
Jun-09-23	Upgrade	Raymond James	Outperform → Strong Buy	$50 → $75
Jun-07-23	Initiated	H.C. Wainwright	Buy	$55
May-17-23	Initiated	Raymond James	Outperform	$50
Apr-28-23	Initiated	Cantor Fitzgerald	Overweight	$45
Apr-21-23	Initiated	Stifel	Buy	$37
Apr-20-23	Initiated	Morgan Stanley	Overweight	$37
Mar-23-23	Initiated	BMO Capital Markets	Outperform	$40
Feb-28-23	Initiated	SVB Securities	Outperform	$36

Show Previous Ratings

Today 03:04PM	Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP (GlobeNewswire) -21.91%
Jan-28-26 09:55AM	Wall Street Analysts Believe Disc Medicine, Inc. (IRON) Could Rally 48.62%: Here's is How to Trade (Zacks)
Jan-16-26 01:34PM	Disc Medicine Analyst Remains Confident In Rare Disease Drug Despite FDA Action (Benzinga)
Jan-15-26 02:09PM	State Street's crypto push, FDA delays review of Eli Lilly GLP-1 (Yahoo Finance Video) -7.84%
08:26AM	FDA Shows Caution, Delays Trump-Backed Fast-Track Drugs Over Risks (Benzinga)
04:59PM	Loading…
Jan-13-26 04:59PM	Health Care Roundup: Market Talk (The Wall Street Journal)
Jan-12-26 04:30PM	Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer (GlobeNewswire)
08:30AM	Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026 (GlobeNewswire)
Jan-07-26 08:30AM	Disc Medicine to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-26-25 05:14PM	Seadrill, Vestis, Mastercraft Boat, and More Stocks See Action From Activist Investors (Barrons.com)
Dec-11-25 07:44AM	Leering Partners Lifts Disc Medicine, Inc. (IRON) Following EPP Drug NDA Application (Insider Monkey)
Dec-09-25 12:20AM	This is Why Disc Medicine, Inc. (IRON) is a Buy on Wall Street (Insider Monkey)
Dec-06-25 08:00AM	Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Nov-06-25 08:30AM	Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Nov-03-25 09:00AM	Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
08:30AM	Loading…
Oct-31-25 08:30AM	Disc Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-27-25 12:00PM	What Makes Disc Medicine, Inc. (IRON) a Strong Momentum Stock: Buy Now? (Zacks)
Oct-22-25 09:55AM	Does Disc Medicine, Inc. (IRON) Have the Potential to Rally 26.29% as Wall Street Analysts Expect? (Zacks)
Oct-21-25 12:14AM	Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Oct-20-25 08:25AM	FDA Grants First CNPV Vouchers, Igniting Rally in Biotech Stocks (GuruFocus.com)
07:00AM	Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
06:30AM	Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones (GlobeNewswire)
Oct-17-25 10:17AM	The FDA Just Granted Its Speediest Review Ever. Disc Medicine, Others Fly. (Investor's Business Daily) +20.95%
09:00AM	Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week (GlobeNewswire)
Oct-16-25 05:35PM	Disc Medicine Announces Receipt of FDA Commissioner's National Priority Voucher (CNPV) for Bitopertin in Erythropoietic Protoporphyria (EPP) (GlobeNewswire)
Sep-30-25 08:30AM	Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP) (GlobeNewswire)
Aug-27-25 08:30AM	Disc Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-22-25 05:16PM	Rapid7, Residio Tech, and 4 More Stocks See Action From Activist Investors (Barrons.com)
Aug-07-25 08:30AM	Disc Medicine Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-28-25 10:05AM	Disc Medicine, Inc. (IRON) Set to Submit NDA for Bitopertin in October 2025 (Insider Monkey)
09:15AM	Loading…
Jul-22-25 09:15AM	OrbiMed Promotes Mona Ashiya to General Partner (PR Newswire)
Jul-21-25 08:00AM	Disc Medicine Announces Positive Pre-NDA Meeting and Confirms Plans to Submit NDA for Bitopertin in Erythropoietic Protoporphyria (EPP) in October 2025 (GlobeNewswire)
Jul-14-25 08:30AM	Disc Medicine Appoints Nadim Ahmed to its Board of Directors (GlobeNewswire)
Jul-10-25 12:39AM	Morgan Stanley Assumes Coverage of Disc Medicine (IRON) With $85 PT (Insider Monkey)
Jun-24-25 05:42PM	Leerink Partners Reiterates a Buy Rating on Disc Medicine (IRON) With an $85 Price Target (Insider Monkey) +6.42%
Jun-15-25 05:42AM	Raymond James Resumes Coverage on Disc Medicine (IRON) With a Strong Buy Rating (Insider Monkey)
Jun-12-25 07:30AM	Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress (GlobeNewswire)
Jun-11-25 09:45AM	Raymond James bullish on biotech firms on favorable valuation (Investing.com)
May-28-25 04:01PM	Disc Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-14-25 09:30AM	Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress (GlobeNewswire)
May-13-25 08:00AM	Disc Medicine to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference (GlobeNewswire)
May-07-25 08:00AM	Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Apr-29-25 08:00AM	Disc Medicine to Host Webinar with Key Opinion Leaders on Anemia of Myelofibrosis (MF) (GlobeNewswire)
Apr-09-25 07:13AM	Disc Medicine: Forging Ahead In Hematology (Seeking Alpha) +12.89%
Mar-26-25 09:39PM	Is Disc Medicine, Inc. (NASDAQ:IRON) the Best Small Cap Stock to Buy Before They Explode? (InsiderMonkey)
Mar-21-25 06:35PM	Victorias Secret, Bitdeer, and More Stocks See Activist Action (Barrons.com)
Mar-14-25 12:00PM	All You Need to Know About Disc Medicine, Inc. (IRON) Rating Upgrade to Buy (Zacks)
Mar-03-25 09:55AM	Wall Street Analysts Predict a 68.78% Upside in Disc Medicine, Inc. (IRON): Here's What You Should Know (Zacks)
Feb-27-25 08:00AM	Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-26-25 08:00AM	Disc Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-12-25 09:55AM	Disc Medicine, Inc. (IRON) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Jan-23-25 08:28AM	Disc raises $225.5m as it eyes approval of rare skin disorder drug (Pharmaceutical Technology)
Jan-22-25 09:35PM	Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Jan-21-25 04:01PM	Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
07:45AM	Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission (GlobeNewswire)
Jan-20-25 07:00PM	Disc Medicine to Host Conference Call on Type C Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP) (GlobeNewswire)
Jan-17-25 04:00PM	Disc Medicine Reports Inducement Grant under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Jan-10-25 09:00AM	Disc Medicine Highlights Recent Achievements Across Hematology Portfolio and Key Business Objectives and Milestones for 2025 (GlobeNewswire) -5.27%
Dec-09-24 12:00PM	Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Dec-08-24 08:00PM	Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Nov-24-24 06:10AM	Raymond James Predicts Up to ~440% Rally for These 2 Strong Buy Stocks (TipRanks)
Nov-13-24 08:30AM	Disc Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-12-24 08:00AM	Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-11-24 10:38AM	Disc Medicine secures $200m financing to support trials (Clinical Trials Arena)
Nov-08-24 08:30AM	Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc. (GlobeNewswire)
Nov-05-24 09:00AM	Disc Medicine Announces Multiple Presentations Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) +11.20%
Nov-04-24 01:44PM	Disc teases potential NDA for rare skin disorder drug (Pharmaceutical Technology) +23.59%
07:50AM	Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval (GlobeNewswire)
Nov-01-24 04:01PM	Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP) (GlobeNewswire) +5.15%
Oct-25-24 01:00PM	Disc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney Week (GlobeNewswire)
Oct-23-24 08:00AM	Disc Medicine Appoints Seasoned Industry Executive Rahul Kaushik, Ph.D. as Chief Technical Officer (GlobeNewswire) -7.72%
Oct-11-24 08:00AM	Disc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2024 American Society of Nephrology (ASN) Kidney Week (GlobeNewswire)
Sep-19-24 08:30AM	Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffe, MD as Chief Regulatory Officer (GlobeNewswire)
08:30AM	Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caff , MD as Chief Regulatory Officer (GlobeNewswire)
Aug-30-24 08:00AM	Disc Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 08:00AM	Disc Medicine Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jun-28-24 08:11PM	Bitfarms Technologies, Vestis, and More Stocks See Action From Activist Investors (Barrons.com)
Jun-14-24 08:03AM	Disc Medicine Announces Underwritten Offering of Common Stock (GlobeNewswire) +18.16%
07:30AM	Disc Medicine Presents Positive Clinical Data Across Portfolio at the European Hematology Association (EHA) 2024 Congress (GlobeNewswire)
May-30-24 09:00AM	Disc Medicine to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-14-24 10:30AM	Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress (GlobeNewswire)
May-13-24 08:00AM	Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference (GlobeNewswire)
May-11-24 05:31AM	Disc Medicine Inc (IRON) Reports Q1 2024 Earnings: A Detailed Financial Overview (GuruFocus.com)
May-09-24 01:54PM	IRON Stock Earnings: Disc Medicine Misses EPS for Q1 2024 (InvestorPlace)
08:00AM	Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-02-24 02:24PM	Disc Medicine (IRON) Down on Mixed Results From AURORA Study (Zacks) -6.36%
Apr-01-24 04:19PM	Disc Medicine Plummets After Placebo Effect Confounds Sunlight Sensitivity Study (Investor's Business Daily) -45.05%
08:00AM	Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) (GlobeNewswire)
Mar-23-24 05:31AM	Disc Medicine Inc (IRON) Reports Earnings: A Detailed Look at Fiscal Performance (GuruFocus.com)
Mar-21-24 08:00AM	Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire) -7.52%
Mar-06-24 04:30PM	Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024 (GlobeNewswire) -5.18%
Feb-26-24 08:30AM	Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer (GlobeNewswire)
Feb-20-24 08:30AM	Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease (GlobeNewswire)
Feb-09-24 09:00AM	Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera (GlobeNewswire)
Feb-07-24 08:00AM	Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer (GlobeNewswire)
Jan-03-24 05:00PM	Disc Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-22-23 06:35PM	Peabody Energy, Janus International, and More Stocks See Action From Activist Investors (Barrons.com)
Dec-20-23 04:30PM	Disc Medicine Announces Retirement of Brian MacDonald, MB, ChB, PhD as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board (GlobeNewswire)
Dec-15-23 03:01PM	Insider Sell Alert: Director William White Sells 33,511 Shares of Disc Medicine Inc (IRON) (GuruFocus.com)
Dec-11-23 08:30PM	Disc Presents Positive Updated Results from Phase 2 BEACON Study of Bitopertin and Other Programs at the 65th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Khara Rahul	Chief Legal Officer	Jan 20 '26	Option Exercise	13.50	1,000	13,500	38,793	Jan 21 06:55 PM
Khara Rahul	Chief Legal Officer	Jan 20 '26	Sale	69.74	1,000	69,740	37,793	Jan 21 06:55 PM
Khara Rahul	Chief Legal Officer	Jan 02 '26	Option Exercise	13.50	6,500	87,750	44,293	Jan 05 08:02 PM
Khara Rahul	Chief Legal Officer	Jan 02 '26	Sale	78.69	6,500	511,472	37,793	Jan 05 08:02 PM
RAHUL KHARA	Officer	Jan 02 '26	Proposed Sale	79.41	7,500	595,575		Jan 02 04:30 PM
Savage William Jacob	Chief Medical Officer	Dec 22 '25	Option Exercise	9.97	3,143	31,350	78,845	Dec 29 08:50 PM
Quisel John D	Chief Executive Officer	Dec 19 '25	Option Exercise	1.01	12,300	12,423	184,128	Dec 19 06:16 PM
Bitterman Kevin	Director	Dec 17 '25	Sale	91.47	754	68,968	14,013	Dec 18 06:14 PM
AI DMI LLC	Affiliate	Dec 17 '25	Proposed Sale	87.49	50	4,374		Dec 17 07:48 PM
Atlas Venture Fund XII, LP	Shareholder	Dec 17 '25	Proposed Sale	91.47	148	13,538		Dec 17 05:08 PM
Atlas Venture Opportunity Fund	Shareholder	Dec 17 '25	Proposed Sale	91.47	213	19,483		Dec 17 05:07 PM
Atlas Venture Opportunity Fund	Shareholder	Dec 17 '25	Proposed Sale	91.47	393	35,948		Dec 17 05:06 PM
Atlas Venture Fund X, LP	Shareholder	Dec 17 '25	Proposed Sale	91.47	818	74,822		Dec 17 05:05 PM
Bitterman Kevin	Director	Dec 15 '25	Option Exercise	13.50	7,000	94,500	7,000	Dec 16 09:43 PM
Bitterman Kevin	Director	Dec 16 '25	Sale	91.24	68,923	6,288,535	14,161	Dec 16 09:43 PM
Bitterman Kevin	Director	Dec 15 '25	Sale	91.28	62,693	5,722,608	28,520	Dec 16 09:43 PM
Bitterman Kevin	Director	Dec 12 '25	Sale	92.39	45,507	4,204,407	41,519	Dec 16 09:43 PM
Bitterman Kevin	Director	Dec 15 '25	Sale	91.87	7,000	643,090	0	Dec 16 09:43 PM
Savage William Jacob	Chief Medical Officer	Dec 15 '25	Sale	91.22	13,093	1,194,372	75,702	Dec 16 09:31 PM
AI DMI LLC	Affiliate	Dec 16 '25	Proposed Sale	91.47	39,769	3,637,670		Dec 16 06:27 PM
Atlas Venture Opportunity Fund	Shareholder	Dec 16 '25	Proposed Sale	92.00	10,898	1,002,616		Dec 16 05:18 PM
Atlas Venture Fund XII, LP	Shareholder	Dec 16 '25	Proposed Sale	92.00	4,359	401,028		Dec 16 05:18 PM
Atlas Venture Opportunity Fund	Shareholder	Dec 16 '25	Proposed Sale	92.00	5,666	521,272		Dec 16 05:17 PM
Atlas Venture Fund X, LP	Shareholder	Dec 16 '25	Proposed Sale	92.00	22,666	2,085,272		Dec 16 05:16 PM
Atlas Venture Opportunity Fund	Shareholder	Dec 16 '25	Proposed Sale	91.47	25,000	2,286,750		Dec 16 05:15 PM
Atlas Venture Fund X, L.P.	Shareholder	Dec 16 '25	Proposed Sale	91.47	52,000	4,756,440		Dec 16 05:03 PM
Atlas Venture Opportunity Fund	Shareholder	Dec 16 '25	Proposed Sale	91.47	13,000	1,189,110		Dec 16 04:59 PM
Atlas Venture Associates XII,	Shareholder	Dec 16 '25	Proposed Sale	91.47	10,000	914,700		Dec 16 04:56 PM
AI DMI LLC	Affiliate	Dec 15 '25	Proposed Sale	92.00	5,843	537,556		Dec 15 07:52 PM
Atlas Venture Opportunity Fund	Shareholder	Dec 15 '25	Proposed Sale	92.00	8,851	814,292		Dec 15 06:56 PM
Atlas Venture Opportunity Fund	Shareholder	Dec 15 '25	Proposed Sale	92.00	17,433	1,603,836		Dec 15 06:56 PM
Atlas Venture Fund X, L.P.	Shareholder	Dec 15 '25	Proposed Sale	92.00	36,877	3,392,684		Dec 15 06:50 PM
Atlas Venture Associates XII,	Shareholder	Dec 15 '25	Proposed Sale	92.00	6,839	629,188		Dec 15 06:44 PM
Quisel John D	Chief Executive Officer	Dec 11 '25	Option Exercise	9.86	40,000	394,400	211,828	Dec 15 05:49 PM
Quisel John D	Chief Executive Officer	Dec 11 '25	Sale	93.05	40,000	3,721,931	171,828	Dec 15 05:49 PM
KEVIN J BITTERMAN	Officer	Dec 15 '25	Proposed Sale	91.87	7,000	643,061		Dec 15 05:45 PM
Atlas Venture Opportunity Fund	Shareholder	Dec 15 '25	Proposed Sale	91.85	8,009	735,627		Dec 15 05:40 PM
Atlas Venture Fund XII, LP	Shareholder	Dec 15 '25	Proposed Sale	91.85	6,160	565,796		Dec 15 05:37 PM
Atlas Venture Opportunity Fund	Shareholder	Dec 15 '25	Proposed Sale	91.85	15,401	1,414,582		Dec 15 05:35 PM
Atlas Venture Fund X, LP	Shareholder	Dec 15 '25	Proposed Sale	91.85	32,035	2,942,415		Dec 15 05:34 PM
WILLIAM SAVAGE	Officer	Dec 15 '25	Proposed Sale	91.85	13,093	1,202,592		Dec 15 04:14 PM
AI DMI LLC	Affiliate	Dec 12 '25	Proposed Sale	91.85	29,388	2,699,288		Dec 12 09:50 PM
Atlas Venture Fund XII, LP	Shareholder	Dec 12 '25	Proposed Sale	93.60	9,481	887,422		Dec 12 05:15 PM
Atlas Venture Opportunity Fund	Shareholder	Dec 12 '25	Proposed Sale	93.60	12,325	1,153,620		Dec 12 05:13 PM
Atlas Venture Opportunity Fund	Shareholder	Dec 12 '25	Proposed Sale	93.60	23,701	2,218,414		Dec 12 05:11 PM
Atlas Venture Fund X, LP	Shareholder	Dec 12 '25	Proposed Sale	93.60	49,299	4,614,386		Dec 12 05:10 PM
JOHN QUISEL	Director	Dec 11 '25	Proposed Sale	92.85	40,000	3,714,000		Dec 11 04:25 PM
Yu Jonathan Yen-Wen	Chief Operating Officer	Nov 11 '25	Option Exercise	2.65	30,000	79,500	70,555	Nov 13 08:22 PM
Yu Jonathan Yen-Wen	Chief Operating Officer	Nov 11 '25	Sale	84.70	30,000	2,540,923	40,555	Nov 13 08:22 PM
JONATHAN YU	Officer	Nov 11 '25	Proposed Sale	83.58	30,000	2,507,400		Nov 12 06:56 AM
AI DMI LLC	10% Owner	Oct 22 '25	Sale	80.47	744,047	59,873,462	2,814,379	Oct 24 04:01 PM
OrbiMed Private Investments VI	Shareholder	Oct 20 '25	Proposed Sale	89.94	482,308	43,378,782		Oct 20 08:54 PM
OrbiMed Genesis Master Fund, L	Shareholder	Oct 20 '25	Proposed Sale	89.94	186,541	16,777,498		Oct 20 08:52 PM
OrbiMed Private Investments VI	Shareholder	Oct 20 '25	Proposed Sale	89.94	746,171	67,110,620		Oct 20 08:47 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 17 '25	Proposed Sale	89.94	35,000	3,147,900		Oct 17 05:26 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 17 '25	Proposed Sale	89.94	35,000	3,147,900		Oct 17 05:23 PM
Atlas Venture Fund X, LP	Shareholder	Oct 17 '25	Proposed Sale	74.36	50,000	3,718,000		Oct 17 04:42 PM
Bitterman Kevin	Director	Oct 17 '25	Sale	88.91	70,000	6,223,934	385,549	Oct 17 04:41 PM
Bitterman Kevin	Director	Oct 15 '25	Sale	77.23	22,160	1,711,436	478,461	Oct 17 04:41 PM
Bitterman Kevin	Director	Oct 16 '25	Sale	77.11	1,425	109,882	477,036	Oct 17 04:41 PM
Atlas Venture Fund X, LP	Shareholder	Oct 16 '25	Proposed Sale	76.98	1,425	109,696		Oct 16 04:46 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 16 '25	Proposed Sale	76.98	1,425	109,696		Oct 16 04:46 PM
Atlas Venture Fund X, LP	Shareholder	Oct 15 '25	Proposed Sale	73.00	22,160	1,617,680		Oct 15 05:00 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 15 '25	Proposed Sale	73.00	22,160	1,617,680		Oct 15 05:00 PM
Bitterman Kevin	Director	Oct 08 '25	Sale	70.58	71,961	5,079,007	500,621	Oct 09 04:07 PM
Bitterman Kevin	Director	Oct 07 '25	Sale	68.38	18,039	1,233,493	572,582	Oct 09 04:07 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 08 '25	Proposed Sale	67.89	71,961	4,885,432		Oct 08 04:55 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 07 '25	Proposed Sale	69.28	18,039	1,249,742		Oct 07 05:16 PM
Quisel John D	Chief Executive Officer	Sep 09 '25	Option Exercise	1.01	10,000	10,100	171,828	Sep 11 06:00 PM
Bitterman Kevin	Director	Aug 22 '25	Sale	61.03	2,287	139,576	590,621	Aug 26 06:01 PM
Atlas Venture Opportunity Fund	Shareholder	Aug 22 '25	Proposed Sale	59.75	2,287	136,648		Aug 22 04:29 PM
Atlas Venture Fund X, L.P.	Shareholder	Aug 22 '25	Proposed Sale	59.75	4,080	243,780		Aug 22 04:25 PM
Bitterman Kevin	Director	Aug 13 '25	Sale	61.15	24,962	1,526,426	600,120	Aug 15 07:23 PM
Bitterman Kevin	Director	Aug 14 '25	Sale	60.99	7,212	439,860	592,908	Aug 15 07:23 PM
Atlas Venture Opportunity Fund	Shareholder	Aug 14 '25	Proposed Sale	61.10	7,212	440,653		Aug 14 04:24 PM
Atlas Venture Fund X, L.P.	Shareholder	Aug 14 '25	Proposed Sale	61.10	12,862	785,868		Aug 14 04:16 PM
Atlas Venture Opportunity Fund	Shareholder	Aug 13 '25	Proposed Sale	59.03	24,962	1,473,507		Aug 13 04:26 PM
Atlas Venture Fund X, L.P.	Shareholder	Aug 13 '25	Proposed Sale	59.03	44,520	2,628,016		Aug 13 04:24 PM
Bitterman Kevin	Director	Aug 05 '25	Sale	60.95	395	24,075	625,082	Aug 07 05:00 PM
Atlas Venture Opportunity Fund	Shareholder	Aug 05 '25	Proposed Sale	59.79	395	23,617		Aug 05 04:31 PM
Atlas Venture Fund X, L.P.	Shareholder	Aug 05 '25	Proposed Sale	59.79	705	42,152		Aug 05 04:24 PM
Bitterman Kevin	Director	Jul 30 '25	Sale	61.04	8,492	518,352	625,477	Aug 01 04:32 PM
Atlas Venture Opportunity Fund	Shareholder	Jul 30 '25	Proposed Sale	59.80	8,492	507,822		Jul 30 04:18 PM
Atlas Venture Fund X, L.P.	Shareholder	Jul 30 '25	Proposed Sale	59.80	15,146	905,731		Jul 30 04:14 PM
Bitterman Kevin	Director	Jul 23 '25	Sale	60.97	29,837	1,819,162	647,002	Jul 25 05:22 PM
Bitterman Kevin	Director	Jul 24 '25	Sale	61.17	13,033	797,229	633,969	Jul 25 05:22 PM
Atlas Venture Opportunity Fund	Shareholder	Jul 24 '25	Proposed Sale	60.94	13,033	794,231		Jul 24 04:27 PM
Atlas Venture Fund X, L.P.	Shareholder	Jul 24 '25	Proposed Sale	60.94	23,245	1,416,550		Jul 24 04:25 PM
Atlas Venture Opportunity Fund	Shareholder	Jul 23 '25	Proposed Sale	60.74	29,837	1,812,299		Jul 23 04:30 PM
Atlas Venture Fund X, L.P.	Shareholder	Jul 23 '25	Proposed Sale	60.74	53,215	3,232,279		Jul 23 04:25 PM
Bitterman Kevin	Director	Jul 18 '25	Sale	61.13	664	40,590	676,839	Jul 22 04:44 PM
Franchi Jean M.	Chief Financial Officer	Jul 17 '25	Sale	59.00	2,031	119,829	63,499	Jul 18 04:51 PM
Atlas Venture Opportunity Fund	Shareholder	Jul 18 '25	Proposed Sale	57.79	664	38,373		Jul 18 04:33 PM
Atlas Venture Fund X, L.P.	Shareholder	Jul 18 '25	Proposed Sale	57.79	1,184	68,423		Jul 18 04:31 PM
JEAN FRANCHI	Officer	Jul 17 '25	Proposed Sale	57.34	2,031	116,458		Jul 17 04:20 PM
Franchi Jean M.	Chief Financial Officer	Jul 10 '25	Sale	57.50	2,000	115,000	65,530	Jul 14 09:36 PM
Quisel John D	Chief Executive Officer	Jul 09 '25	Option Exercise	9.86	34,800	343,128	196,628	Jul 11 04:48 PM
Quisel John D	Chief Executive Officer	Jul 09 '25	Sale	55.33	34,800	1,925,525	161,828	Jul 11 04:48 PM
JEAN FRANCHI	Officer	Jul 10 '25	Proposed Sale	55.86	2,000	111,720		Jul 10 04:34 PM
JOHN QUISEL	Director	Jul 09 '25	Proposed Sale	52.97	34,800	1,843,356		Jul 09 04:17 PM

STTK

Shattuck Labs Inc

IRON

Disc Medicine Inc

Upgrade your FINVIZ experience